These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10566280)

  • 1. [Alzheimer disease: efficacy and tolerance of rivastagmine].
    Hébert M
    Presse Med; 1999 Oct; 28(32):1757-8. PubMed ID: 10566280
    [No Abstract]   [Full Text] [Related]  

  • 2. Rivastigmine for Alzheimer's disease.
    Drug Ther Bull; 2000 Feb; 38(2):15-6. PubMed ID: 10829350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].
    Schölzel-Dorenbos CJ
    Ned Tijdschr Geneeskd; 2002 Mar; 146(10):494. PubMed ID: 11913117
    [No Abstract]   [Full Text] [Related]  

  • 4. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spontaneous rupture of oesophagus (Boerhaave's syndrome) related to rivastigmine.
    Babic T; Banfic L; Papa J; Barisic N; Jelincic Z; Zurak N
    Age Ageing; 2000 Jul; 29(4):370-1. PubMed ID: 10985453
    [No Abstract]   [Full Text] [Related]  

  • 6. Brief review: rivastigmine, a second cholinesterase inhibitor.
    Patterson C; Hogan DB
    Can J Neurol Sci; 2001 Feb; 28 Suppl 1():S122-3. PubMed ID: 11237306
    [No Abstract]   [Full Text] [Related]  

  • 7. Rivastigmine (Exelon) for Alzheimer's disease.
    Med Lett Drugs Ther; 2000 Oct; 42(1089):93-4. PubMed ID: 11015159
    [No Abstract]   [Full Text] [Related]  

  • 8. Does rivastigmine improve cognitive functions or disability in patients with Alzheimer's disease?
    Cantisani TA; Celani MG; Righetti E
    Neuroepidemiology; 2004; 23(4):209-10. PubMed ID: 15272224
    [No Abstract]   [Full Text] [Related]  

  • 9. [Oestro-progestagen treatment combined with rivastigmine in menopausal women suffering from Alzheimer's disease. The results of a 28-weeks controlled study].
    Rigaud AS; André G; Vellas B; Touchon J; Pere JJ; Loria-Kanza Y
    Presse Med; 2003 Oct; 32(35):1649-54. PubMed ID: 14631268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivastigmin and impaired motor function.
    Heinze M; Andreae D; Grohmann R
    Pharmacopsychiatry; 2002 Mar; 35(2):79-80. PubMed ID: 11951151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of rivastigmine in Alzheimer's disease. Participation in trials should be based on clinical uncertainty, not enforcement.
    Bullock R; Passmore P; Wilkinson D; Howard R; Jones R
    BMJ; 2000 Feb; 320(7233):511-2. PubMed ID: 10678874
    [No Abstract]   [Full Text] [Related]  

  • 12. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease.
    Jann MW
    Pharmacotherapy; 2000 Jan; 20(1):1-12. PubMed ID: 10641971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Alzheimer disease. Pseudo-irreversible AChE inhibition with rivastigmine].
    Med Monatsschr Pharm; 1998 Aug; 21(8):248-9. PubMed ID: 9758554
    [No Abstract]   [Full Text] [Related]  

  • 14. Prolonged QT interval with rivastigmine.
    Walsh E; Dourish J
    Br J Psychiatry; 2002 May; 180():466. PubMed ID: 11983648
    [No Abstract]   [Full Text] [Related]  

  • 15. Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine.
    Linkins KW; Lloyd JR; Hjelmstad GO; Strausbaugh HJ
    Pharmacoeconomics; 2000 Dec; 18(6):609-12. PubMed ID: 11227398
    [No Abstract]   [Full Text] [Related]  

  • 16. Rivastigmine in outpatient services: experience of 114 neurologists in Austria.
    Schmidt R; Lechner A; Petrovic K
    Int Clin Psychopharmacol; 2002 Mar; 17(2):81-5. PubMed ID: 11890189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug treatment of Alzheimer's disease and responders to rivastigmine beyond 12 weeks.
    McMillan H
    Int J Geriatr Psychiatry; 1999 Dec; 14(12):1078-9. PubMed ID: 10607978
    [No Abstract]   [Full Text] [Related]  

  • 18. Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients.
    Adler G; Brassen S
    Neuropsychobiology; 2001; 43(4):273-6. PubMed ID: 11340368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivastigmine in vascular dementia.
    Moretti R; Torre P; Antonello RM; Cazzato G; Bava A
    Expert Opin Pharmacother; 2004 Jun; 5(6):1399-410. PubMed ID: 15163283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].
    Richard E; Walstra GJ; van Campen J; Vissers E; van Gool WA
    Ned Tijdschr Geneeskd; 2002 Jan; 146(1):24-7. PubMed ID: 11802333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.